Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Otodine
- Development stage
- Unknown
- Lead developer
- Nextmune
- Modality
- Small Molecules
- Administration
- Otic
01
Overview
Otodine is a patented veterinary ear-cleansing solution developed by Nextmune for dogs and cats. It contains a combination of chlorhexidine digluconate and Tris-EDTA, buffered to pH 8. The formulation acts as an antimicrobial and ceruminolytic agent, targeting common otic pathogens such as *Staphylococcus*, *Pseudomonas*, and *Malassezia*. It is indicated for cleaning the ear canal, removing excess wax, and as an adjunct to medical treatment for otitis externa. The Tris-EDTA component enhances the permeability of bacterial cell walls, synergizing with the antimicrobial action of chlorhexidine to effectively manage ear infections and maintain long-term ear health in companion animals.
- Brand names
- Otodine
Beyond the preview
Go deeper on Otodine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Otodine.